Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 8:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 317 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatitis b Virus Clear all
Completed Phase 2 Interventional Results available

A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)

NCT04449029
View directory record Official record
Conditions
Hepatitis B
Interventions
GSK3228836, Placebo, Nucleos(t)ide therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 28, 2026, 8:32 PM EDT
Completed No phase listed Observational

Hepatitis B Research Network Adult Cohort Study

NCT01263587
View directory record Official record
Conditions
Hepatitis B
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2,051 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Honolulu, Hawaii + 11 more
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 28, 2026, 8:32 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation

NCT00065507
View directory record Official record
Conditions
Hepatitis B
Interventions
Entecavir (ETV), Adefovir (ADV)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
16
States / cities
San Diego, California • San Francisco, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 28, 2026, 8:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine

NCT01005407
View directory record Official record
Conditions
Healthy
Interventions
HEPLISAV and/or Placebo, Engerix-B
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
40 Years to 70 Years
Enrollment
2,452 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
29
States / cities
Huntsville, Alabama • San Diego, California • Santa Ana, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 28, 2026, 8:32 PM EDT
Terminated No phase listed Observational

An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

NCT03692897
View directory record Official record
Conditions
Hepatitis B, Hepatitis, Liver Diseases
Interventions
All approved therapies for the treatment of Chronic Hepatitis B (CHB)
Other
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
30
States / cities
Phoenix, Arizona • Los Angeles, California • Pasadena, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 28, 2026, 8:32 PM EDT
Completed Phase 1 Interventional

Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects

NCT02431312
View directory record Official record
Conditions
Hepatitis B
Interventions
INO-1800, INO-9112, Nucleos(t)ide Analogue Treatment
Biological · Drug
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
San Diego, California • Miami, Florida • Manhasset, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 28, 2026, 8:32 PM EDT
Completed No phase listed Observational Results available

S1204, Viral Screening in Newly Diagnosed Cancer Patients

NCT01946516
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
3,051 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
58
States / cities
Fontana, California • Harbor City, California • Martinez, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 28, 2026, 8:32 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen

NCT01940341
View directory record Official record
Conditions
HBeAg-negative Chronic Hepatitis B
Interventions
TAF, TDF, TAF Placebo, TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Oct 28, 2026, 8:32 PM EDT
Not listed Phase 2 Interventional

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy

NCT00281502
View directory record Official record
Conditions
Hepatic Encephalopathy, Hepatitis C, Liver Cirrhosis
Interventions
Rifaximin (drug)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2010 · Synced Oct 28, 2026, 8:32 PM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus

NCT00496002
View directory record Official record
Conditions
Chronic Hepatitis, Hepatitis B
Interventions
Clevudine, Adefovir
Drug
Lead sponsor
Pharmasset
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Anaheim, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2009 · Synced Oct 28, 2026, 8:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants

NCT06058390
View directory record Official record
Conditions
Hepatitis B
Interventions
Bepirovirsen
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 28, 2026, 8:32 PM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy

NCT07658976
View directory record Official record
Conditions
HIV Infection, Sexually Transmitted Infection
Interventions
HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP, 3P mHealth package, Handout about HIV PrEP options available at the site, Standard-of-care HIV PrEP counseling from qualified study staff
Drug · Behavioral
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years to 29 Years · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Los Angeles, California • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 28, 2026, 8:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus

NCT01627340
View directory record Official record
Conditions
Hepatitis B
Interventions
Engerix™-B vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years and older
Enrollment
667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
10
States / cities
Huntsville, Alabama • Stockbridge, Georgia • Boise, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 28, 2026, 8:32 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

NCT00412750
View directory record Official record
Conditions
Hepatitis B
Interventions
Telbivudine (LdT), peginterferon alpha-2a
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Oct 28, 2026, 8:32 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

DV2-HBV-27: Observational Pregnancy Registry

NCT03664648
View directory record Official record
Conditions
Pregnant
Interventions
HEPLISAV-B
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 28, 2026, 8:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Immunologic Memory (Supp. of ATN 024)

NCT00142753
View directory record Official record
Conditions
HIV Infections
Interventions
Engerix B, Twinrix for ATN 024, Recombivax, Twinrix for ATN 025
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 25 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
4
States / cities
Los Angeles, California • San Franciso, California • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 28, 2026, 8:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterization of Clonal B Cell Populations in HCV Infection

NCT00435201
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 28, 2026, 8:32 PM EDT
Completed Phase 2 Interventional Results available

HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)

NCT03685708
View directory record Official record
Conditions
Hepatitis, Safety and Tolerability
Interventions
HEPLISAV-B
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 28, 2026, 8:32 PM EDT
Completed Phase 3 Interventional Results available

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis

NCT02201901
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
49
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 28, 2026, 8:32 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

NCT04980482
View directory record Official record
Conditions
Chronic Hepatitis b
Interventions
AB-729, Peg-IFNα-2a
Drug
Lead sponsor
Arbutus Biopharma Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Chandler, Arizona • Tucson, Arizona • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 28, 2026, 8:32 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

NCT01311674
View directory record Official record
Conditions
Healthy Volunteers
Interventions
hepatitis B vaccine
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
20 Years to 55 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Altamonte Springs, Florida • Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 28, 2026, 8:32 PM EDT
Not yet recruiting Not applicable Interventional

HIV/HBV/HCV Triple Screening in Primary Care

NCT07031219
View directory record Official record
Conditions
HIV, HBV (Hepatitis B Virus), HCV
Interventions
electronic medical record alert linked to orders
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 28, 2026, 8:32 PM EDT
Completed Phase 3 Interventional

Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection

NCT00023153
View directory record Official record
Conditions
HIV Infections, Chronic Hepatitis B
Interventions
Adefovir Dipivoxil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 8:32 PM EDT
Completed Phase 3 Interventional Results available

Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies

NCT00142298
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Telbivudine (LdT)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
16 Years to 70 Years
Enrollment
1,869 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • Pasadena, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 28, 2026, 8:32 PM EDT